ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2181

Antiphospholipid Antibody-Mediated Increase of Tissue Factor in Arterial Wall Is Associated with Increased Thrombus Size in a Mouse Model

Pierre Grant1, Rohan Willis2, Zurina Romay-Penabad1, Elizabeth Papalardo3, Mohammad Jamaluddin4, Rajani Rudrangi3, Emilio B Gonzalez5 and Allan R Brasier6, 1University of Texas Medical Branch, Galveston, TX, 2Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 3Internal Medicine, Rheumatology, University of Texas Medical Branch, Galveston, TX, 4Institute for Translational Science, University of Texas Medical Branch, Galveston, TX, 5Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX, 6Internal Medicine and Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Antiphospholipid and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Antiphospholipid Syndrome: Basic Science

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Antiphospholipid syndrome (APS) is a multisystemic autoimmune disease characterized by recurrent thrombotic and adverse obstetric events in the presence of antiphospholipid antibodies (aPL). Compelling data indicate a key role for aPL-mediated induction of tissue factor (TF) expression in monocytes and endothelial cells in the pathogenesis of APS. Recent in-vivo data from our group utlizing low TF producing mice demonstrated the importance of TF in aPL-mediated thrombosis. There is however limited in-vivo data demonstrating the source of TF in the vessel wall in thrombosis resulting from aPL activity.

The aim of this study was to determine the major sources of TF expression in the arterial wall of mice subjected to passive aPL administration.

Methods:

CD1 male mice (n=5 per group) were inoculated with either purified whole IgG from an APS patient (IgG-APS) with high IgG aPL and documented aterial and venous thrombosis or with whole IgG from normal human serum (IgG-NHS). Antibodies were purified from serum using diethylaminoethanol (DEAE) sepharose and adjusted to the appropriate concentration in phosphate buffered saline and any endotoxin present was removed by a commercially available column (Thermo Scientific). Mice were treated with the IgG solutions twice intraperitoneally, the second inoculation given 48 hours after the first, and surgery to measure thrombus dynamics of thrombi induced by a standardized pinch injury to the femoral vein and to collect the aorta was done 72 hours after first inoculation. Staining for TF in the aortic wall was performed by immunohistochemistry using an anti-TF primary antibody, an Alexa-Fluor 586 conjugated secondary antibody and 4′,6-diamidino-2-phenylindole(DAPI) counterstain on formalin fixed and paraffin embedded aorta specimens.

Results:

The mean thrombus size was significantly larger in IgG-APS treated mice (1747.4±362.6 um2) compared to those given IgG-NHS (613.6±127.3um2) (p<0.001). Staining for TF in the aortic wall of IgG-NHS mice revealed minimal staining in the media and moderately more intense staining in the adventitia. In IgG-APS treated mice, there was consistently intense TF staining in the adventitia and moderate staining in the media, noticeably greater than that seen in NHS treated mice.

Conclusion:

In this mouse model, IgG aPL induced significantly larger thrombi than control IgG and was associated with a noticeable increase in adventitial and medial TF, with the adventitia being the major source. Further study is needed to determine the specific cellular sources of TF important in aPL-mediated thrombosis.


Disclosure: P. Grant, None; R. Willis, None; Z. Romay-Penabad, None; E. Papalardo, None; M. Jamaluddin, None; R. Rudrangi, None; E. B. Gonzalez, None; A. R. Brasier, None.

To cite this abstract in AMA style:

Grant P, Willis R, Romay-Penabad Z, Papalardo E, Jamaluddin M, Rudrangi R, Gonzalez EB, Brasier AR. Antiphospholipid Antibody-Mediated Increase of Tissue Factor in Arterial Wall Is Associated with Increased Thrombus Size in a Mouse Model [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/antiphospholipid-antibody-mediated-increase-of-tissue-factor-in-arterial-wall-is-associated-with-increased-thrombus-size-in-a-mouse-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphospholipid-antibody-mediated-increase-of-tissue-factor-in-arterial-wall-is-associated-with-increased-thrombus-size-in-a-mouse-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology